Meeting
2019 Gastrointestinal Cancers Symposium
Identifying the importance of integrating routine pharmacogenomic testing for UGT1A1 and DPYD/tyms genetic variants in patients receiving irinotecan and/or 5-fluorouracil chemotherapy.
Authors
Candice Baldeo
Mayo Clinic, Jacksonville, FL
Candice Baldeo , Caren Hughes , Faisal Shahjehan , Saivaishnavi Kamatham , Pashtoon Murtaza Kasi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 660)
DOI
10.1200/JCO.2019.37.4_suppl.660
Abstract #
660
Poster Bd #
M5
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Feasibility and value of incorporating pharmacogenomic testing for genetic variants in UGT1A1 and DPYD genes in patients receiving irinotecan and/or 5-fluorouracil chemotherapy.
First Author: Candice Baldeo
Poster
2015 ASCO Annual Meeting
DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.
First Author: Marzia Del Re
Poster
2023 ASCO Annual Meeting
Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.
First Author: Jai Narendra Patel
Poster
2021 ASCO Annual Meeting
Pre-therapeutic dihydropyridimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity.
First Author: Côme De Metz